+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer



Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer



New England Journal of Medicine 341(27): 2039-2048



Two years after undergoing resection of liver metastases from colorectal cancer, about 65 percent of patients are alive and 25 percent are free of detectable disease. We tried to improve these outcomes by treating patients with hepatic arterial infusion of floxuridine plus systemic fluorouracil after liver resection. We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone. Patients were stratified according to previous treatment and the number of liver metastases identified at operation. The study end points were overall survival, survival without recurrence of hepatic metastases, and survival without any metastases at two years. The actuarial rate of overall survival at two years was 86 percent in the group treated with local plus systemic chemotherapy and 72 percent in the group given systemic therapy alone (P=0.03). The median survival was 72.2 months in the combined-therapy group and 59.3 months in the monotherapy group, with a median follow-up of 62.7 months. After two years, the rates of survival free of hepatic recurrence were 90 percent in the monotherapy group and 60 percent in the monotherapy group (P<0.001), and the respective rates of progression-free survival were 57 percent and 42 percent (P=0.07). At two years, the risk ratio for death was 2.34 among patients treated with systemic therapy alone, as compared with patients who received combined therapy (95 percent confidence interval, 1.10 to 4.98; P=0.027), after adjustment for important variables. The rates of adverse effects of at least moderate severity were similar in the two groups, except for a higher frequency of diarrhea and hepatic effects in the combined-therapy group. For patients who undergo resection of liver metastases from colorectal cancer, postoperative treatment with a combination of hepatic arterial infusion of floxuridine and intravenous fluorouracil improves the outcome at two years.

(PDF emailed within 0-6 h: $19.90)

Accession: 059792838

Download citation: RISBibTeXText

PMID: 10615075

DOI: 10.1056/NEJM199912303412702


Related references

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. Gastroenterologie Clinique et Biologique 24(6-7): 690-691, 2000

Study of hepatic arterial infusion chemotherapy for prophylaxis of liver metastases of colorectal cancer after hepatic resection. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 22(11): 1497-1499, 1995

Indication of prophylactic hepatic arterial-infusion chemotherapy after hepatic resection for liver metastases from colorectal cancer. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 23(11): 1457-1460, 1996

Indication for hepatic resection after hepatic arterial infusion chemotherapy for multiple liver metastases of colorectal cancer. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 27(12): 1834-1837, 2000

Treatment of liver metastases from colorectal cancer--major hepatic resection and continuous hepatic arterial infusion chemotherapy. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 17(4 Pt 2): 777-781, 1990

The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer. Nihon Geka Gakkai Zasshi 101(8): 568-573, 2000

Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Annals of Surgical Oncology 10(4): 348-354, 2003

Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection. Hepato-Gastroenterology 59(116): 1087-1090, 2012

Clinical results of pharmacokinetic modulating chemotherapy (PMC) in combination with hepatic arterial 5FU infusion, continuous venous 5FU infusion and oral UFT as adjuvant chemotherapy after liver resection for hepatic colorectal metastases. Journal of Clinical Oncology 23(16_suppl): 3665-3665, 2016

Evaluation of hepatic resection following hepatic arterial infusion chemotherapy for colorectal liver metastases. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 27(12): 1826-1829, 2000

Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer. Journal of Gastrointestinal Oncology 6(6): 699-708, 2015

Evaluation of prophylactic intra-hepatic-arterial infusion chemotherapy after resection of hepatic metastases from colorectal primaries. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 21(13): 2158-2161, 1994

Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 89(6): 1228-1235, September 15, 2000

Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Annals of Surgery 257(1): 114-120, 2013

Evaluation of continuous intra-arterial infusion chemotherapy after hepatic resection of liver metastases in colorectal cancer. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 18(11): 1935-1939, 1991